MedTrace Logo

A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.

NCT00444782 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2008-12-18

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy of GV1001 in locally advanced or metastatic HCC. Also the safety of GV1001 and immunogenicity will be evaluated.

Conditions

  • Carcinoma, Hepatocellular

Interventions

BIOLOGICAL

GV1001

Sponsors & Collaborators

  • Pharmexa A/S

    lead INDUSTRY

Principal Investigators

  • Lotte Rosendahl, Pharmacist (CTM) · Pharmexa A/S

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • France
  • Germany
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00444782 on ClinicalTrials.gov